GeneSight® Shown to Statistically Significantly Improve Generalized Anxiety Disorder Treatment Response and Decrease Benzodi...
October 19 2017 - 7:05AM
Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc.
(NASDAQ:MYGN), today announced new positive results for the
GeneSight® test in patients with Generalized Anxiety Disorder
(GAD). The study found that GeneSight guided treatment
statistically significantly improved treatment response in patients
with GAD and decreased the use of benzodiazepines which have
potential for abuse and dependence. The data were presented
at the 25th World Congress of Psychiatric Genetics meeting in
Orlando, Fla with co-investigators from Toronto’s Centre for
Addiction and Mental Health (CAMH).
“Anxiety is one of the most common mental health
disorders, affecting 60 million Americans or three times the number
of people with depression,” said Bryan Dechairo, Ph.D., executive
vice president of Clinical Development, Myriad Genetics.
“This new study provides strong evidence that the GeneSight test
can help physicians personalize treatment for patients with
anxiety, leading to more effective treatment and a beneficial
reduction in benzodiazepine use.”
This study evaluated data from two separate studies
including: CAMH’s Individualized Medicine: Pharmacogenetic
Assessment and Clinical Treatment (IMPACT) study, where 315
patients with anxiety disorders were assessed for symptom severity
using the GAD-7 questionnaire; and the Medco dataset in which 662
patients who were prescribed at least one benzodiazepine six months
pretesting and were followed 12 months post-testing.
The results of the IMPACT study show that
medication decisions that were congruent with the GeneSight test
results can help guide the treatment of GAD and resulted in a
statistically-significant improvement in anxiety symptom severity
(p=0.03). The Medco data showed that 18 percent of patients
originally taking at least one benzodiazepine ceased the use of
benzodiazepines after testing with GeneSight with a significant
decrease in benzodiazepine drug counts and refills
(p<0.001). The IMPACT study was funded in part by
Ontario’s Ministry of Research and Innovation.
For more information about GeneSight, please
visit www.genesight.com.
About AnxietyAnxiety affects
one in five people in the United States and one in nine people
worldwide and is a leading cause of disability. Anxiety
increases the risk for other conditions including depression and
substance abuse. Treatment for anxiety includes psychological
interventions and pharmacologic therapy. Antidepressants are
considered the first line in the treatment of anxiety and
benzodiazepines are considered second or third line due to the
potential for abuse and dependency.
About
GeneSight®GeneSight is a
laboratory-developed pharmacogenomic test that uses cutting edge
technology to measure and analyze clinically important genomic
variants in the treatment of psychiatric disorders. The results of
the GeneSight report can help a clinician understand the way a
patient’s unique genomic makeup may affect certain psychiatric
drugs. The analysis is based on pharmacogenomics, the study of
genomic factors that influence an individual’s response to drug
treatments, manufacturers’ FDA approved drug labels, peer reviewed
scientific and clinical publications, and proven drug pharmacology.
Quick turnaround time, combined with a customized report of
the patient’s genomic makeup, clinical experience, and other
factors can provide information to help a physician make
personalized drug treatment choices for each patient.
About Assurex HealthAssurex Health, a
wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN) is a
personalized medicine company that specializes in pharmacogenomics
and is dedicated to helping physicians determine the right
medication for individual patients with neuropsychiatric and other
disorders. The company was founded to commercialize
industry-leading personalized medicine technology for
neuropsychiatric disorders. Assurex Health has licensed technology
from Mayo Clinic and Cincinnati Children’s Hospital Medical
Center.
For more information about Assurex Health,
please visit https://genesight.com/about-assurex-health/ .
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
three strategic imperatives: maintaining leadership in an
expanding hereditary cancer market, diversifying its product
portfolio through the introduction of new products and increasing
the revenue contribution from international markets. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com. Myriad, the Myriad logo,
BART, BRACAnalysis, Colaris, Colaris AP, EndoPredict, myPath,
myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan,
BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra DA,
GeneSight, EndoPredict and Prolaris are trademarks or registered
trademarks of Myriad Genetics, Inc. or its wholly owned
subsidiaries in the United States and foreign countries. MYGN-F,
MYGN-G
About CAMH The Centre for Addiction and Mental
Health (CAMH) is Canada's largest mental health and addiction
teaching hospital, as well as one of the world's leading research
centres in its field. CAMH combines clinical care, research,
education, policy development and health promotion to help
transform the lives of people affected by mental health and
addiction issues. CAMH is fully affiliated with the University of
Toronto, and is a Pan American Health Organization/World Health
Organization Collaborating Centre. For more information, please
follow @CAMHnews and @CAMHResearch on Twitter.
Safe Harbor StatementThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to related to data presented at the 25th World
Congress of Psychiatric Genetics meeting in Orlando, Fla.;
GeneSight testing being able to statistically significantly improve
generalized anxiety disorder treatment response and decrease
benzodiazepine use; the study providing strong evidence that the
GeneSight test can help physicians personalize treatment for
patients with anxiety, leading to more effective treatment and a
beneficial reduction in benzodiazepine use; and the Company’s
strategic directives under the caption “About Myriad Genetics.”
These “forward-looking statements” are based on management’s
current expectations of future events and are subject to a number
of risks and uncertainties that could cause actual results to
differ materially and adversely from those described or implied in
the forward-looking statements. These risks include, but are not
limited to: the risk that sales and profit margins of our existing
molecular diagnostic tests and pharmaceutical and clinical services
may decline or will not continue to increase at historical rates;
risks related to our ability to transition from our existing
product portfolio to our new tests; risks related to changes in the
governmental or private insurers’ reimbursement levels for our
tests or our ability to obtain reimbursement for our new tests at
comparable levels to our existing tests; risks related to increased
competition and the development of new competing tests and
services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services tests and any future tests are terminated or
cannot be maintained on satisfactory terms; risks related to delays
or other problems with operating our laboratory testing facilities;
risks related to public concern over genetic testing in general or
our tests in particular; risks related to regulatory requirements
or enforcement in the United States and foreign countries and
changes in the structure of the healthcare system or healthcare
payment systems; risks related to our ability to obtain new
corporate collaborations or licenses and acquire new technologies
or businesses on satisfactory terms, if at all; risks related to
our ability to successfully integrate and derive benefits from any
technologies or businesses that we license or acquire, including
but not limited to our acquisition of Assurex, Sividon and the
Clinic; risks related to our projections about the potential market
opportunity for our products; the risk that we or our licensors may
be unable to protect or that third parties will infringe the
proprietary technologies underlying our tests; the risk of
patent-infringement claims or challenges to the validity of our
patents; risks related to changes in intellectual property laws
covering our molecular diagnostic tests and pharmaceutical and
clinical services and patents or enforcement in the United States
and foreign countries, such as the Supreme Court decision in the
lawsuit brought against us by the Association for Molecular
Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; the risk that we may be unable to comply with
financial operating covenants under our credit or lending
agreements; the risk that we will be unable to pay, when due,
amounts due under our credit or lending agreements; and other
factors discussed under the heading “Risk Factors” contained in
Item 1A of our most recent Annual Report on Form 10-K, which has
been filed with the Securities and Exchange Commission, as well as
any updates to those risk factors filed from time to time in our
Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.
Media Contact: Ron Rogers(801) 584-3065
rrogers@myriad.com
Investor Contact: Scott
Gleason(801) 584-1143sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024